(Q45363333)

13 December 2017

Hepatitis B virus drug resistance to current nucleos(t)ide analogs: Mechanisms and mutation sites (English)

1 reference

13 December 2017

1 reference

Lihui Deng

1

1 reference

PubMed ID

21917087

13 December 2017

Hong Tang

series ordinal

2

1 reference

13 December 2017

15 September 2011

1 reference

13 December 2017

1 reference

13 December 2017

41

1 reference

13 December 2017

11

1 reference

13 December 2017

1017-1024

1 reference

Management of hepatitis B: summary of a clinical research workshop

13 December 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00873.X

Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00873.X

Chronic hepatitis B: update 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00873.X

Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00873.X

Hepatitis B virus resistance to nucleos(t)ide analogues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00873.X

Antiviral therapy and resistance with hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00873.X

Drug resistance in antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00873.X

Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00873.X

Differential impact of immune escape mutations G145R and P120T on the replication of lamivudine-resistant hepatitis B virus e antigen-positive and -negative strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00873.X

Hepatitis B virus escape mutants induced by antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00873.X

Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00873.X

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00873.X

Antiviral drug resistance: clinical consequences and molecular aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00873.X

Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00873.X

Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00873.X

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00873.X

Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00873.X

The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00873.X

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00873.X

Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00873.X

The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00873.X

Polymerase domain B mutation is associated with hepatitis relapse during long-term lamivudine therapy for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00873.X

Emergence of a novel mutation in the FLLA region of hepatitis B virus during lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00873.X

Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00873.X

Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00873.X

Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00873.X

The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00873.X

Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00873.X

Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00873.X

Adefovir dipivoxil in chronic hepatitis B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00873.X

A novel hepatitis B virus mutation with resistance to adefovir but not to tenofovir in an HIV-hepatitis B virus-co-infected patient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00873.X

Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00873.X

Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00873.X

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00873.X

Variant of hepatitis B virus with primary resistance to adefovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00873.X

Hepatitis B virus containing the I233V mutation in the polymerase reverse-transcriptase domain remains sensitive to inhibition by adefovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00873.X

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00873.X

Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00873.X

Evolution of multi-drug resistant hepatitis B virus during sequential therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00873.X

2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00873.X

In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00873.X

Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00873.X

Prolonged use of tenofovir in HIV/hepatitis B virus (HBV)-coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00873.X

Clinical trial results of new therapies for HBV: implications for treatment guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00873.X

Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00873.X

Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00873.X

Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00873.X

The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00873.X

Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2011.00873.X

10.1111/J.1872-034X.2011.00873.X

21 January 2018

Identifiers

DOI

1 reference

13 December 2017

1 reference

PubMed ID

21917087